Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2013; 34(02): 96-98
DOI: 10.4103/0971-5851.116187
CASE REPORT

Long-term survivor of human immunodeficiency virus-associated plasmablastic lymphoma

Atul Sharma
Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, New Delhi, India
,
T. V. S. V. G. K. Tilak
Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, New Delhi, India
,
Rakesh Lodha
Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
,
M.C. Sharma
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India
,
Deepak Dabkara
Department of Medical Oncology, Tata Medical Centre, Rajarhat, Kolkata, West Bengal, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

Plasmablastic lymphoma (PL) is a type of non-Hodgkin′s lymphoma (NHL) having a strong association with immunosuppression, especially, human immunodeficiency virus (HIV) infection. It generally has a poor prognosis with most patients dying within 2 years from initial presentation, and long-term survivors are very few. We report the case of a 10-years-old child, presenting in 2003 with swelling on the right side of the face and fever of 2 months. Evaluation revealed a mass in the right palatal and upper alveolar region with extensive spread and bone destruction, regional adenopathy, mass lesion in the liver and hepatosplenomegaly without bone marrow involvement. Histopathology was suggestive of the PL and patient tested positive for HIV. He was started on high grade NHL chemotherapy protocol along with highly-active anti-retroviral therapy HAART. He responded well and is in complete remission since 8 years of completion of treatment and is on HAART.

Keywords

Human immunodeficiency virus-associated non-Hodgkin′s lymphoma - long-term survivor - plasmablastic lymphoma


Publication History

Article published online:
20 July 2021

© 2013. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Delecluse HJ, Anagnostopoulos I, Dallenbach F, Hummel M, Marafioti T, Schneider U, et al. Plasmablastic lymphomas of the oral cavity: A new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413-20.
  • 2 Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: Changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 2006;19:14-9.
  • 3 Clarke CA, Glaser SL. Epidemiologic trends in HIV-associated lymphomas. Curr Opin Oncol 2001;13:354-9.
  • 4 Nasta SD, Carrum GM, Shahab I, Hanania NA, Udden MM. Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy. Leuk Lymphoma2002;43:423-6.
  • 5 Lester R, Li C, Phillips P, Shenkier TN, Gascoyne RD, Galbraith PF, et al. Improved outcome of human immunodeficiency virus-associated plasmablastic lymphoma of the oral cavity in the era of highly active antiretroviral therapy: A report of two cases. Leuk Lymphoma 2004;45:1881-5.
  • 6 Panos G, Karveli EA, Nikolatou O, Falagas ME. Prolonged survival of an HIV-infected patient with plasmablastic lymphoma of the oral cavity. Am J Hematol 2007;82:761-5.
  • 7 Nicol I, Boye T, Carsuzaa F, Feier L, Collet Villette AM, Xerri L, et al. Post-transplant plasmablastic lymphoma of the skin. Br J Dermatol 2003;149:889-91.
  • 8 Advani S, Pai S, Adde M, Vaidya S, Vats T, Naresh K, et al. Preliminary report of an intensified, short duration chemotherapy protocol for the treatment of pediatric non-Hodgkin′s lymphoma in India. Ann Oncol 1997;8:893-7.
  • 9 Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000;96:2730-4.
  • 10 Fisher SG, Fisher RI. The epidemiology of non-Hodgkin′s lymphoma. Oncogene 2004;23:6524-34.
  • 11 Montes-Moreno S, Gonzalez-Medina AR, Rodriguez-Pinilla SM, Maestre L, Sanchez-Verde L, Roncador G, et al. Aggressive large B-cell lymphoma with plasma cell differentiation: Immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica 2010;95:1342-9.
  • 12 Castillo J, Dezube BJ, Pantanowitz L. Plasmablastic lymphoma in HIV. J Clin Oncol 2008;26:19519.
  • 13 Dong HY, Scadden DT, deLeval L, Tang Z, Isaacson PG, Harris NL. Plasmablastic lymphoma in HIV-positive patients: An aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol 2005;29:1633-41.
  • 14 Flaitz CM, Nichols CM, Walling DM, Hicks MJ. Plasmablastic lymphoma: An HIV-associated entity with primary oral manifestations. Oral Oncol 2002;38:96-102.